The role of endomyocardial biopsy in the management of cardiovascular disease: A Scientific Statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology

摘要: The role of endomyocardial biopsy (EMB) in the diagnosis and treatment adult pediatric cardiovascular disease remains controversial, practice varies widely even among centers excellence. A need for EMB exists because specific myocardial disorders that have unique prognoses are seldom diagnosed by noninvasive testing.1 Informed clinical decision making weighs risks against incremental diagnostic, prognostic, therapeutic value procedure is especially challenging nonspecialists relevant published literature usually cited according to cardiac diseases, which only after EMB. To define current management disease, a multidisciplinary group experts cardiomyopathies pathology was convened American Heart Association (AHA), College Cardiology (ACC), European Society (ESC). present Writing Group charged with reviewing on summarizing this information, useful recommendations classifications levels evidence. The identified 14 scenarios could be estimated compared procedural risks. contained joint Scientific Statement derived from comprehensive review cardiomyopathies, arrhythmias, tumors categorized presenting syndrome rather than pathologically confirmed disease. ultimate intent document provide an understanding range acceptable approaches use while recognizing individual patient care decisions depend factors not well reflected literature, such as local availability specialized facilities, expertise, operator experience. …